RADX 6-K
Radiopharm Theranostics Ltd (RADX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 3, 2025 titled:
“Change of Director’s Interest Notice (RC)”
“Presenting at Deutsche Bank ADR Virtual Investor Conference”
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit <br><br>Number | Description |
|---|---|
| 99.1 | Change of Director’s Interest Notice (RC) |
| 99.2 | Presenting at Deutsche Bank ADR Virtual Investor Conference |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
|---|---|---|
| Date: November 3, 2025 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary |
3
Exhibit 99.1
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced30/9/2001. Amended 01/01/11
| Name ofEntity: | Radiopharm Theranostics Limited (ASX: RAD) |
|---|---|
| ABN: | 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director: | Riccardo Canevari |
|---|---|
| Date of Last Notice: | 18 December 2024 |
Part 1 - Changeof director’s relevant interests in securities
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or Indirect Interest | Indirect | ||
|---|---|---|---|
| Nature of indirect interest<br><br> <br>(including registered holder)<br><br> <br>Note: Provide details of the circumstances<br> giving rise to the relevant interest. | Indirect interest held via broker nominee account | ||
| Date of change | 30 October 2025 | ||
| No. of securities held prior to change | Shares | Options | |
| **** | 20,029,986 | 110,949,299 | |
| **** | 1,150,000 | - | |
| **** | 21,179,986 | 110,949,299 | |
| Class | RAD ORDINARY FULLY PAID SHARES | ||
| Numberacquired | Shares | Options | |
| **** | - | - | |
| **** | 1,500,000 | - | |
| **** | 1,500,000 | - | |
| Number disposed | Shares | Options | |
| **** | - | - | |
| **** | - | - | |
| **** | - | - | |
| Value/Consideration<br><br> <br>Note:<br><br> <br>If consideration is non-cash, provide details<br> and estimated valuation | 0.025 per share |
All values are in US Dollars.
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 1 |
Appendix 3Y
Change of Director’s Interest Notice
| No. of securities held after change | Shares | Options | ||
|---|---|---|---|---|
| **** | Direct | 20,029,986 | 110,949,299 | |
| **** | Indirect | 2,650,000 | - | |
| **** | Total | 22,679,986 | 110,949,299 | |
| Nature of change<br><br> <br>Example:<br><br> <br>on-market trade, off-market trade, exercise<br> of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market trade |
Part 2 –Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change<br><br> <br>Note: Details<br> are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration<br><br> <br>Note: If consideration is non-cash, provide details<br> and an estimated valuation | N/A |
| Interest after change | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Y Page 2 | 01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – Closed period
| Were the interestsin the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
|---|---|
| 01/01/2011 | Appendix 3Y Page 3 |
Exhibit 99.2
| ASX ANNOUNCEMENT3 NOVEMBER 2025 |
|---|
Radiopharm Theranostics to Present at the dbVIC— Deutsche Bank ADR Virtual Investor Conference
Individual and institutional investors, advisorsand analysts invited to attend online at VirtualInvestorConferences.com
Sydney, Australia – 3 November 2025 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, will present live at the dbVIC – Deutsch Bank American Depositary Receipt (ADR) Virtual Investor Conference.
The event is being hosted by VirtualInvestorConferences.com on 4 November 2025. This virtual conference program is aimed exclusively at introducing global companies with ADR programs to investors.
DATE: Tuesday 4 November 2025
TIME: 12:30pm EST (US) / 4:30am AEDT, Wednesday 5 November 2025 (Sydney)
LINK: Click here to visit the website and register
This will be a live, interactive online event where investors are invited to ask management questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Participation is free of charge.
Recent Company Highlights
| ● | Raised approximately A$35 million in capital through an institutional private placement to new Australian<br>and international investors with a potential A$5 million through a Share Purchase Plan for existing shareholders in Australia and New<br>Zealand. |
|---|---|
| ● | Reported preliminary data from the first three patients in a Phase 2b imaging clinical trial of RAD 101<br>that showed uptake in brain metastases from solid tumours, confirming proof-of-concept with Phase 2 topline results expected by H1 2026. |
| --- | --- |
| ● | Announced that the first cohort of patients in its Phase 1 clinical trial of RAD 202 (HER2) showed a higher-than-expected<br>tumour uptake, with a second cohort of patients anticipated to be fully enrolled with data available by year-end 2025. |
| --- | --- |
| ● | Highlighted additional data from the first six patients in a Phase 1 clinical trial of RAD 204 (PDL-1),<br>which showed promising tumour uptake. |
| --- | --- |
| ● | Noted data from the Phase 1 study of RAD 301 supported the decision to advance to a Phase 2 imaging trial<br>in patients with loco-regional pancreatic cancer. |
| --- | --- |
Radiopharm Theranostics LimitedSuite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 AustraliaABN: 57 647 877 889
| ASX ANNOUNCEMENT3 NOVEMBER 2025 |
|---|
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
About Virtual Investor Conferences^®^
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Authorised on behalf of the Radiopharm Theranostics Board of Directorsby Executive Chairman Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
Radiopharm Theranostics LimitedSuite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 AustraliaABN: 57 647 877 889
2
| ASX ANNOUNCEMENT3 NOVEMBER 2025 |
|---|
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics LimitedSuite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 AustraliaABN: 57 647 877 889
3